Oriol Albert, Motlló Cristina
Servicio de Hematología clínica y Unidad de investigación Clínica, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras, Badalona, Barcelona, España.
Servicio de Hematología clínica y Unidad de investigación Clínica, Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia Josep Carreras, Badalona, Barcelona, España.
Med Clin (Barc). 2014 Sep 15;143(6):268-74. doi: 10.1016/j.medcli.2013.10.012. Epub 2013 Dec 15.
Progress in the treatment of multiple myeloma in the last decade has been able to delay, but ultimately not to prevent, the development of resistances and most patients still die of the disease or its related complications. New drugs have been developed including new alkylating agents, proteasome inhibitors and immunomodulators but also monoclonal antibodies and drugs with new mechanisms of action. Hopefully, this new generation of targeted agents will improve the results of the initial therapy, avoid relapses and development of resistances and provide better and less toxic options for the relapsed and refractory patient.
过去十年间，多发性骨髓瘤的治疗虽有进展，能够延缓但最终无法阻止耐药性的出现，大多数患者仍死于该病或其相关并发症。已研发出多种新药，包括新型烷化剂、蛋白酶体抑制剂、免疫调节剂，还有单克隆抗体以及具有新作用机制的药物。有望新一代靶向药物能改善初始治疗效果，避免复发和耐药性的产生，并为复发及难治性患者提供毒性更低的更好选择。
